Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen M Hewitt

Showing results (331-340 of 413) with videos related to

Pageof 42
Sort By:
Scientific Data|June 25, 2024
Characterization of an expanded set of assays for immunomodulatory proteins using targeted mass spectrometryJeffrey R Whiteaker, Lei Zhao, Regine M Schoenherr, et al.
Journal for Immunotherapy of Cancer|February 8, 2023
Phase I/II study of PexaVec in combination with immune checkpoint inhibition in refractory metastatic colorectal cancerCecilia Monge, Changqing Xie, Yuta Myojin, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|January 25, 2023
Successful lung transplantation using an allograft from a COVID-19-recovered donor: a potential role for subgenomic RNA to guide organ utilizationKapil K Saharia, Sabrina C Ramelli, Sydney R Stein, et al.
Cell Death & Disease|September 20, 2019
Epigenetic re-wiring of breast cancer by pharmacological targeting of C-terminal binding proteinJung S Byun, Samson Park, Dae Ik Yi, et al.
Science Immunology|July 12, 2024
Initiator cell death event induced by SARS-CoV-2 in the human airway epitheliumKaixin Liang, Katherine C Barnett, Martin Hsu, et al.
Autophagy|August 9, 2020
LC3B upregulation by NANOG promotes immune resistance and stem-like property through hyperactivation of EGFR signaling in immune-refractory tumor cellsSuyeon Kim, Hanbyoul Cho, Soon-Oh Hong, et al.
Cancer Research|July 19, 2017
HDAC1 Upregulation by NANOG Promotes Multidrug Resistance and a Stem-like Phenotype in Immune Edited Tumor CellsKwon-Ho Song, Chel Hun Choi, Hyo-Jung Lee, et al.
Journal for Immunotherapy of Cancer|October 23, 2019
Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymomaArun Rajan, Christopher R Heery, Anish Thomas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 6, 2007
Dissecting the Akt/mammalian target of rapamycin signaling network: emerging results from the head and neck cancer tissue array initiativeAlfredo A Molinolo, Stephen M Hewitt, Panomwat Amornphimoltham, et al.
Communications Biology|February 2, 2021
Kaiso (ZBTB33) subcellular partitioning functionally links LC3A/B, the tumor microenvironment, and breast cancer survivalSandeep K Singhal, Jung S Byun, Samson Park, et al.
Pageof 42

Showing results (331-340 of 413) with videos related to

Sort By:
Pageof 42
Scientific Data|June 25, 2024
Characterization of an expanded set of assays for immunomodulatory proteins using targeted mass spectrometryJeffrey R Whiteaker, Lei Zhao, Regine M Schoenherr, et al.
Journal for Immunotherapy of Cancer|February 8, 2023
Phase I/II study of PexaVec in combination with immune checkpoint inhibition in refractory metastatic colorectal cancerCecilia Monge, Changqing Xie, Yuta Myojin, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|January 25, 2023
Successful lung transplantation using an allograft from a COVID-19-recovered donor: a potential role for subgenomic RNA to guide organ utilizationKapil K Saharia, Sabrina C Ramelli, Sydney R Stein, et al.
Cell Death & Disease|September 20, 2019
Epigenetic re-wiring of breast cancer by pharmacological targeting of C-terminal binding proteinJung S Byun, Samson Park, Dae Ik Yi, et al.
Science Immunology|July 12, 2024
Initiator cell death event induced by SARS-CoV-2 in the human airway epitheliumKaixin Liang, Katherine C Barnett, Martin Hsu, et al.
Autophagy|August 9, 2020
LC3B upregulation by NANOG promotes immune resistance and stem-like property through hyperactivation of EGFR signaling in immune-refractory tumor cellsSuyeon Kim, Hanbyoul Cho, Soon-Oh Hong, et al.
Cancer Research|July 19, 2017
HDAC1 Upregulation by NANOG Promotes Multidrug Resistance and a Stem-like Phenotype in Immune Edited Tumor CellsKwon-Ho Song, Chel Hun Choi, Hyo-Jung Lee, et al.
Journal for Immunotherapy of Cancer|October 23, 2019
Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymomaArun Rajan, Christopher R Heery, Anish Thomas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 6, 2007
Dissecting the Akt/mammalian target of rapamycin signaling network: emerging results from the head and neck cancer tissue array initiativeAlfredo A Molinolo, Stephen M Hewitt, Panomwat Amornphimoltham, et al.
Communications Biology|February 2, 2021
Kaiso (ZBTB33) subcellular partitioning functionally links LC3A/B, the tumor microenvironment, and breast cancer survivalSandeep K Singhal, Jung S Byun, Samson Park, et al.
Pageof 42